ERBA Group showcases latest technologies at MEDLAB 2019

At the recently concluded MEDLAB expo in Dubai, the ERBA Group, a leading global In-vitro Diagnostic Company, launched their latest hematology analyzers, H 360 and H 560. Designed for improving lab efficiency, these systems are paving the way for better healthcare outcomes in over 100 emerging market countries.

These latest additions are targeted at small to medium laboratories and complement the larger automatic Elite 580 hematology analyzer launched at MEDLAB 2018. The newly launched, H 360 3-part differential analyzer can run up to 60 samples/hr and requires only 9 microlitres of blood. The H 560 5-part differential analyzer also runs 60 samples/hr and requires only 15 microlitres, which is highly beneficial in pediatric cases. In both systems, interpretation of results is aided using an advanced 3D scattergram.

ERBA also displayed the latest version of its powerful Laura XL platform, which is a fully automated urine chemistry and sediment analyzer. Using digital microscopy and AI technology, it auto-recognizes 16 urine sediment elements. Moreover, the photometric urine strip reader aids in precise determination of 10 analytes using ERBA’s standardized test strips DekaPHAN®. 

The ERBA group also hosted an education session by Dr. Mir Majid Mossalaeie, Vice President of Iranian Association of Clinical Laboratory Doctors on the effectiveness of AMH ELISA test kits, which helps childless couples conceive though better estimation of ovarian age.  Dr. Mossalaeie commented on the high quality of ERBA’s AMH kit which is made by its US subsidiary, Calbiotech Inc., along with 200 other immunoassay products.

Further, the ERBA team of experts provided first-hand experience to the delegates on the new systems with more than 10 demonstrations being conducted each day!

The Director-General of Dubai Health Authority, His Excellency Humaid Al Quatami, also visited the booth and witnessed the wide range of technologies being offered by the group.

During the exhibition, customer interactions were complemented by a series of informational presentations conducted by industry experts and ERBA team members. Insightful discussions on the benefits of fast reporting for better treatment outcomes, validation methods for clinical chemistry systems, and the advantages of AMH ELISA testing were held in addition to presentations on Laura XL, H 360 and 560 and Calbiotech’s high quality ELISA test range.

Speaking about ERBA’s participation, Nikhil Vazirani, CEO, ERBA Group, said, “We are glad to be associated with MEDLAB as it offers an opportunity to interact with customers from across the world. ERBA operates in a dynamic global economy and MEDLAB gives us a great opportunity to help understand changing customer needs and how we should adapt our technologies to offer seamless services. We are committed to focusing our products and solutions on the emerging markets and impacting a billion lives globally.”

An annual event, MEDLAB has been successfully operating in the MENA region for over 17 years. Home to hundreds of medical laboratory manufacturers from across 46 countries worldwide, it attracts decision makers at all levels of development, manufacture or marketing of medical devices. Held between 4-7 February 2019 at Dubai World Trade Centre, the event attracted more than 25,000 visitors from 130 countries!